IN-VIVO EFFECT OF SOMATOSTATIN ANALOG, LANREOTIDE, AND/OR GRP ANTAGONIST, BIM-26226, ON THE GROWTH OF COLON-CANCER PERITONEAL CARCINOMATOSIS IN THE RAT

  • Authors:
    • BA GOUYON
    • F REYLDESMARS
    • M LEROMANCER
    • C PIGEON
    • MJM LEWIN
    • T LEHY
  • View Affiliations

  • Published online on: November 1, 1995     https://doi.org/10.3892/ijo.7.5.1167
  • Pages: 1167-1173
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The effect of somatostatin analogue, lanreotide, and bombesin/GRP antagonist, BIM 26226, on the growth of colon cancer peritoneal carcinomatosis in the rat was studied. BDIX rats were i.p. injected with DHD/K12 rat colon cancer cells at day 0 and received from day 3 either lanreotide, BIM 26226, combination of treatments or peptide solvents. At sacrifice, an day 45, no significant difference between groups was observed for peritoneal tumor growth, hepatic metastases, ascite volume and labeling indices in normal colonic mucosa and tumoral tissues. Survival times were similar in other lanreotide-treated and control groups. However, BIM 26226 decreased plasma gastrin level, consistently with a physiological effect of this peptide. Ln all groups, somatostatin and bombesin receptors were found on mucosal and tumoral tissues. Interestingly, bombesin receptor number was higher in severe than in minor cancer stages, contrarily to that of somatostatin receptors. Moreover, an up-regulation of somatostatin and bombesin receptors was observed in BIM 26226- and lanreotide-treated group tumors, respectively, Despite the presence of these specific receptors, lanreotide and BIM 26226 were inactive on tumor growth in this model.

Related Articles

Journal Cover

November 1995
Volume 7 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
GOUYON B, REYLDESMARS F, LEROMANCER M, PIGEON C, LEWIN M and LEHY T: IN-VIVO EFFECT OF SOMATOSTATIN ANALOG, LANREOTIDE, AND/OR GRP ANTAGONIST, BIM-26226, ON THE GROWTH OF COLON-CANCER PERITONEAL CARCINOMATOSIS IN THE RAT. Int J Oncol 7: 1167-1173, 1995
APA
GOUYON, B., REYLDESMARS, F., LEROMANCER, M., PIGEON, C., LEWIN, M., & LEHY, T. (1995). IN-VIVO EFFECT OF SOMATOSTATIN ANALOG, LANREOTIDE, AND/OR GRP ANTAGONIST, BIM-26226, ON THE GROWTH OF COLON-CANCER PERITONEAL CARCINOMATOSIS IN THE RAT. International Journal of Oncology, 7, 1167-1173. https://doi.org/10.3892/ijo.7.5.1167
MLA
GOUYON, B., REYLDESMARS, F., LEROMANCER, M., PIGEON, C., LEWIN, M., LEHY, T."IN-VIVO EFFECT OF SOMATOSTATIN ANALOG, LANREOTIDE, AND/OR GRP ANTAGONIST, BIM-26226, ON THE GROWTH OF COLON-CANCER PERITONEAL CARCINOMATOSIS IN THE RAT". International Journal of Oncology 7.5 (1995): 1167-1173.
Chicago
GOUYON, B., REYLDESMARS, F., LEROMANCER, M., PIGEON, C., LEWIN, M., LEHY, T."IN-VIVO EFFECT OF SOMATOSTATIN ANALOG, LANREOTIDE, AND/OR GRP ANTAGONIST, BIM-26226, ON THE GROWTH OF COLON-CANCER PERITONEAL CARCINOMATOSIS IN THE RAT". International Journal of Oncology 7, no. 5 (1995): 1167-1173. https://doi.org/10.3892/ijo.7.5.1167